ERBB2 and breast carcinoma: Using an in vivo breast cancer model, Korangath et al. [181] recently demonstrated that conjugation of hydroxyethyl-starch-covered iron oxide NPs to trastuzumab increases accumulation in the tumor regardless of HER2 expression—in contrast to their in vitro effectiveness, which required HER2 expression.